APA (7th ed.) Citation

Kurasawa, K., Arai, S., Namiki, Y., Tanaka, A., Takamura, Y., Owada, T., . . . Maezawa, R. (2018). Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford, England), 57(12), 2114-2119. https://doi.org/10.1093/rheumatology/key188

Chicago Style (17th ed.) Citation

Kurasawa, Kazuhiro, Satoko Arai, Yumeko Namiki, Ayae Tanaka, Yuta Takamura, Takayoshi Owada, Masafumi Arima, and Reika Maezawa. "Tofacitinib for Refractory Interstitial Lung Diseases in Anti-melanoma Differentiation-associated 5 Gene Antibody-positive Dermatomyositis." Rheumatology (Oxford, England) 57, no. 12 (2018): 2114-2119. https://doi.org/10.1093/rheumatology/key188.

MLA (9th ed.) Citation

Kurasawa, Kazuhiro, et al. "Tofacitinib for Refractory Interstitial Lung Diseases in Anti-melanoma Differentiation-associated 5 Gene Antibody-positive Dermatomyositis." Rheumatology (Oxford, England), vol. 57, no. 12, 2018, pp. 2114-2119, https://doi.org/10.1093/rheumatology/key188.